Cannabis Science, Inc. is a biotech company based in Irvine, California. The company was incorporated in 2009 and formerly traded under the ticker CBIS on the Over-The-Counter Bulletin Board until October 2019, when their SEC license was revoked.[2]
 | |
| Company type | Private |
|---|---|
| Industry | Pharmaceutical |
| Founded | 2000 (as National Healthcare Technology), reestablished in 2009 |
| Headquarters | Irvine, California, U.S. |
Key people | Raymond C. Dabney (President, CEO, Co-Founder and Director) Robert Melamede (Co-Founder)[1] |
| Products | Pharmaceutical products |
| Website | cannabisscience |
The company's stated goal was to obtain Food and Drug Administration (FDA) approval for cannabis-based medicines, with a focus on treating skin cancer (basal and squamous cell carcinomas),[3] posttraumatic stress disorder[4] and HIV.[3] The FDA has not approved these treatments.[5]
References edit
- ^ Radford, Bill (April 9, 2010). "Company looks to create cannabis-based medicines". The Gazette. Retrieved 2019-06-19.
- ^ Mayani, Mamta. "Cannabis Science enters transition stage as shares halted". Seeking Alpha. Retrieved 5 March 2020.
- ^ a b "Cannabis Science Appoints Former GlaxoSmithKline Global Director of HIV Research Dorothy Bray, Ph.D., to Scientific Advisory Board Focusing on CS-TATI-1 and Other Emerging Scientific Investigations". Cannabisscience.com. 2012-06-14. Retrieved 2012-07-04.
- ^ Fine, Doug (August 3, 2012). Too High to Fail: Cannabis and the New Green Economic Revolution. Penguin. p. 8. ISBN 978-1101588895.
- ^ "קנאביס רפואי". Tuesday, 16 March 2021